Survey of proper use and occurrence of hyperkalemia after administration of MINNEBRO tablets in patients with hypertension-MID-NET Cohort Study
Not Applicable
Recruiting
- Conditions
- hypertension
- Registration Number
- JPRN-jRCT2031200204
- Lead Sponsor
- Matsuoka Yomei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3100
Inclusion Criteria
Prescription of MINNEBRO tablets has commenced during the enrollment period (May 13, 2019 to May 31, 2023).
-The diagnosis of hypertension exists between the first prescription day and 30 days before the first prescription day of this drug during the enrollment period.
-The date of the earliest medical record after the start date of the data period is 180 days or more prior to the date of the first prescription of this drug.
Exclusion Criteria
NONE
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method